NEW YORK – Preventive genomics medicine company Veritas Intercontinental said on Thursday that it has completed a €5 million ($5.8 million) Series B financing round.
The round was led by Charme Capital Partners and Amadeus Capital Partners, who have invested in the Veritas Genetics spinoff firm since it was founded in 2018. They were joined in the Series B round by Stemar Capital Partners and entrepreneur Graham Snudden.
Veritas Intercontinental said it plans to use the financing to strengthen its international expansion efforts, and to develop new operational and technological capabilities. The company focuses on providing patients with access to advanced preventive medicine through the use of whole-genome sequencing. Its signature myGenome test provides information on more than 650 diseases and conditions.
The company also offers tests for maternal-fetal medicine (myNewBorn and myPrenatal NIPT), oncology (myCancerRisk), and cardiovascular health (myCardio).
"The renewed support from Charme and Amadeus, together with our new investors, confirms the initial success and great potential of our company," Veritas Intercontinental CEO Javier de Echevarría said in a statement. "It will allow us to bring the application of whole-genome sequencing to millions of people around the world."